These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 28153916)

  • 1. Effects of vitamin D combined with pioglitazone hydrochloride on bone mineral density and bone metabolism in Type 2 diabetic nephropathy.
    Wang LX; Wang N; Xu QL; Yan W; Dong L; Li BL
    Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28153916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial.
    Bray GA; Smith SR; Banerji MA; Tripathy D; Clement SC; Buchanan TA; Henry RR; Kitabchi AE; Mudaliar S; Musi N; Ratner RE; Schwenke DC; Stentz FB; Reaven PD; DeFronzo RA
    Diabetes Obes Metab; 2013 Oct; 15(10):931-7. PubMed ID: 23551856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.
    Park JS; Cho MH; Nam JS; Yoo JS; Ahn CW; Cha BS; Kim KR; Lee HC
    Eur J Endocrinol; 2011 Jan; 164(1):69-74. PubMed ID: 20961967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of atorvastatin on bone mineral density (BMD) and bone metabolism in elderly males with osteopenia and mild dyslipidemia: a 1-year randomized trial.
    Chen ZG; Cai HJ; Jin X; Lu JH; Wang J; Fang NY
    Arch Gerontol Geriatr; 2014; 59(3):515-21. PubMed ID: 25131773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats.
    Samadfam R; Awori M; Bénardeau A; Bauss F; Sebokova E; Wright M; Smith SY
    J Endocrinol; 2012 Feb; 212(2):179-86. PubMed ID: 22062085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of exenatide, insulin and pioglitazone on bone metabolism in patients with newly diagnosed type 2 diabetes.
    Li R; Xu W; Luo S; Xu H; Tong G; Zeng L; Zhu D; Weng J
    Acta Diabetol; 2015 Dec; 52(6):1083-91. PubMed ID: 26249206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
    DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
    J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
    Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
    Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice.
    Tanimoto M; Fan Q; Gohda T; Shike T; Makita Y; Tomino Y
    Metabolism; 2004 Nov; 53(11):1473-9. PubMed ID: 15536604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density.
    Suzuki K; Kurose T; Takizawa M; Maruyama M; Ushikawa K; Kikuyama M; Sugimoto C; Seino Y; Nagamatsu S; Ishida H
    Diabetes Res Clin Pract; 2005 May; 68(2):117-25. PubMed ID: 15860239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
    Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
    Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of vitamin D status and bone mass according to vitamin D-binding protein genotypes.
    Nimitphong H; Sritara C; Chailurkit LO; Chanprasertyothin S; Ratanachaiwong W; Sritara P; Ongphiphadhanakul B
    Nutr J; 2015 Mar; 14():29. PubMed ID: 25890042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
    Ringe JD; Farahmand P; Schacht E; Rozehnal A
    Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus.
    van Lierop AH; Hamdy NA; van der Meer RW; Jonker JT; Lamb HJ; Rijzewijk LJ; Diamant M; Romijn JA; Smit JW; Papapoulos SE
    Eur J Endocrinol; 2012 Apr; 166(4):711-6. PubMed ID: 22267280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between vascular reactivity and lipids in Mexican-Americans with type 2 diabetes treated with pioglitazone.
    Wajcberg E; Sriwijitkamol A; Musi N; DeFronzo RA; Cersosimo E
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1256-62. PubMed ID: 17244785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial.
    Grey A; Bolland M; Fenwick S; Horne A; Gamble G; Drury PL; Reid IR
    Eur J Endocrinol; 2014 Feb; 170(2):255-62. PubMed ID: 24217934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pioglitazone increases bone marrow fat in type 2 diabetes: results from a randomized controlled trial.
    Grey A; Beckley V; Doyle A; Fenwick S; Horne A; Gamble G; Bolland M
    Eur J Endocrinol; 2012 Jun; 166(6):1087-91. PubMed ID: 22408124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailable vitamin D levels are reduced and correlate with bone mineral density and markers of mineral metabolism in adults with nephrotic syndrome.
    Aggarwal A; Yadav AK; Ramachandran R; Kumar V; Kumar V; Sachdeva N; Khandelwal N; Jha V
    Nephrology (Carlton); 2016 Jun; 21(6):483-9. PubMed ID: 26428957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of diabetes mellitus and diabetic nephropathy on bone and mineral metabolism in T2DM patients.
    Chen H; Li X; Yue R; Ren X; Zhang X; Ni A
    Diabetes Res Clin Pract; 2013 May; 100(2):272-6. PubMed ID: 23522918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.